Alkyl nitrites (poppers)
poppers · alkyl nitrites · amyl nitrite · isopropyl nitrite · isopentyl nitrite · pentyl nitrite · butyl nitrite
What does current UK evidence show?
UK clinical reports document serious poisoning and visual injury, but incomplete surveillance cannot establish a reliable current national trend. The ACMD's recommended explicit exemption from the Psychoactive Substances Act is not an enacted exemption.
Overview
Identity, legal classification, form and pharmacological context
- Drug category
- Inhalants
- Common names
- poppers, alkyl nitrites, amyl nitrite, isopropyl nitrite, isopentyl nitrite, pentyl nitrite, butyl nitrite
- Typical forms
- Volatile liquids sold in small bottles under varied names. ‘Amyl’ is sometimes used loosely for the group and does not prove the presence of amyl nitrite. Labels, packaging and product names are unreliable guides to the precise compound.
- Routes
- Usually encountered through inhalation of vapour. Swallowing the liquid is a poisoning emergency; reported fatalities show that inhalation is not risk-free either. Alkyl nitrites are chemically distinct from nitrous oxide and should not be grouped under its legal or clinical description.
- UK legal classification
- Not MDA-classifiedAlkyl nitrites are not classified under the Misuse of Drugs Act. The ACMD's 2024 review explains that the Psychoactive Substances Act can cover their supply following 2018 case law; it recommended an explicit exemption, not one already in force. The ACMD was still seeking a government response on 21 September 2026. The review also records MHRA advice that recreational alkyl nitrites do not automatically fall under medicines regulations following court judgments. Chemical and product-safety controls remain relevant, including restrictions on isobutyl nitrite. This is not an unrestricted-sale or ‘legal high’ designation.Check government source ↗
- Concise pharmacology
- These compounds relax smooth muscle and dilate blood vessels, involving nitric-oxide signalling. This can produce a brief rush and a fall in blood pressure. Relaxation of the anal sphincter helps explain their use in some sexual contexts; they are not conventional sedative drugs.
Main harms
Concise clinical and polydrug picture
Headache, dizziness, a fast heartbeat, nausea and fainting can occur. Methaemoglobinaemia reduces the blood's ability to carry oxygen and can cause breathlessness, blue or grey skin, confusion, collapse or death. Serious toxicity needs emergency assessment, especially following ingestion.
UK case series describe injury to the central retina, sometimes with blurred or distorted central vision after a single episode or repeated use. Recovery can occur after exposure stops, but it is not guaranteed. New visual symptoms warrant prompt assessment. Case series identify a hazard, not the probability that any individual will develop it.
A characteristic physical dependence or withdrawal syndrome has not been established. Some people report relying on poppers in sexual situations; support should address their actual concerns and circumstances rather than assume either addiction or an absence of difficulty.
Do not combine poppers with PDE5 inhibitors such as sildenafil or tadalafil: the combination can produce a dangerous fall in blood pressure. Ask about erectile-dysfunction products obtained online as well as prescribed medicines. Other substance use can complicate assessment; evidence does not support assigning a precise additional risk to every possible combination.
The liquid should never be swallowed or injected. Ingestion can cause rapidly life-threatening poisoning. A 2025 UK mortality study found that route information and case identification were incomplete, so its historical cases cannot be converted into a current mortality rate. Product identity should be documented when possible; selected tested bottles do not represent the wider market.
Current intelligence status
Assessment, confidence and direction
UK clinical reports document serious poisoning and visual injury, but incomplete surveillance cannot establish a reliable current national trend. The ACMD's recommended explicit exemption from the Psychoactive Substances Act is not an enacted exemption.
Reason: Moderate confidence reflects documented UK clinical hazards and official regulatory analysis. A 2025 mortality study identifies substantial gaps in historical death ascertainment and information on routes. Selected cases establish that severe harm occurs, but cannot quantify current national prevalence, individual risk or a 2026 increase. The legal note separates ACMD advice from legislation and gives the date of the latest verified outstanding-response statement.
Principal source limits: Recommendation for a PSA exemption is not enacted law. Historical and selected clinical evidence cannot quantify current UK use. Records an outstanding response on that date; it is not a legal amendment.
Geography and reference periods are given in each linked source card below. The rating is an editorial evidence judgement, not a probability, clinical risk score or TD priority.The assessment reflects the latest linked evidence and is not a universal severity rating.
Operational implications
Evidence-supported prompts for professional response
Sexual-health, drug and emergency services should ask sensitively about poppers, erectile-dysfunction medicines and other substances. Offer inclusive support, STI prevention and testing according to individual needs, without treating sexual orientation as a risk behaviour. Commissioners should retain referral routes for visual symptoms and acute toxicology advice. Emergency clinicians should consider methaemoglobinaemia when breathlessness and blue or grey discolouration follow exposure; inform the treating team of the product and route. Avoid assuming every episode is conventional sedative overdose. Record ingestion separately from inhalation so local learning does not lose a key distinction.
Record substance, sold identity, route, frequency and combinations; review physical, mental-health and dependence needs.
Use symptom-led assessment and escalate reduced consciousness, seizures, overheating, chest pain or severe agitation.
Triangulate treatment, mortality, testing, hospital and frontline evidence before assigning a local trend.
Related intelligence
Continue into connected platform evidence
Sources & limitations
Direct evidence links, reference periods and status
Alkyl nitrites: exemption consideration
Published8 May 2024; updated 9 Aug 2024Reference periodEvidence and legal review to 2024
Recommendation for a PSA exemption is not enacted law. Historical and selected clinical evidence cannot quantify current UK use.Autumn 2026 work programme update
Published21 Sep 2026Reference periodGovernment responses outstanding in Sep 2026
Records an outstanding response on that date; it is not a legal amendment.An update on deaths in the UK from poppers, with a focus on swallowing fatalities
Published10 Jan 2025Reference periodHistorical UK mortality sources and cases to 2022
Incomplete ascertainment and missing route details prevent calculation of a current national rate or reliable temporal trend.Poppers: legal highs with questionable contents? A case series of poppers maculopathy
Published10 Apr 2017 online; Nov 2017 issueReference period12 patients at Sussex Eye Hospital
Selected cases establish a visual-injury hazard, not incidence. Its historical legal wording should not be used for current legal status.Sildenafil
PublishedCurrent online guidanceReference periodInteractions and adverse effects
Drug-interaction advice is not a comparative population risk estimate; NHS uses the common misnomer amyl nitrate for poppers.Tadalafil
PublishedCurrent online guidanceReference periodInteractions and adverse effects
Interaction risk depends on medicines taken and clinical circumstances; no safe co-use interval is inferred here.Methaemoglobin
PublishedSource page undatedReference periodClinical laboratory interpretation
Explains the physiological hazard and presentation; it does not measure poppers-related incidence.